Proteomics International Laboratories Ltd is raising up to $5.5 million through a $4 million placement and a $1 million Share Purchase Plan at $0.37 per share, offering shareholders a discounted entry and free attaching options.
- Placement of 10.8 million shares at $0.37 raising ~$4 million
- Share Purchase Plan open to eligible shareholders to raise up to $1 million
- Shares offered at 18.5% discount to recent market price
- Free attaching options exercisable at $0.50 included with shares
- Funds earmarked for Promarker test launches and US lab expansion
Capital Raise Overview
Proteomics International Laboratories Ltd (ASX:PIQ) has announced a significant capital raising initiative combining a placement and a Share Purchase Plan (SPP) to raise approximately $5.5 million. The placement involves issuing 10.8 million shares at $0.37 each to sophisticated and institutional investors, expected to raise around $4 million. Alongside this, the company is offering existing eligible shareholders in Australia and New Zealand the opportunity to participate in an SPP to raise up to $1 million.
The shares under both the placement and the SPP are priced at $0.37, representing an 18.5% discount to the volume weighted average price of $0.45 over the five trading days prior to the announcement. This pricing strategy aims to incentivize participation while balancing shareholder value.
Share Purchase Plan Details
The SPP allows eligible shareholders to purchase up to $30,000 worth of shares without brokerage fees, regardless of their existing holding size. The plan is non-underwritten and subject to potential scale-backs at the board’s discretion if oversubscriptions occur. Shareholders will also receive one free attaching option for every two shares subscribed, exercisable at $0.50 until 31 May 2026, mirroring the terms offered in the placement.
Participation is open to shareholders registered by 5:00pm AWST on 17 April 2025 with addresses in Australia or New Zealand. The offer opened on 5 May 2025 and closes on 3 June 2025, with shares expected to be issued shortly after.
Use of Funds and Strategic Outlook
Funds raised will be strategically deployed to accelerate the launch of three Promarker diagnostic tests in Australia and the USA, upgrade clinical diagnostic systems in Australia, and establish laboratory platforms in the US for PromarkerD, PromarkerEndo, and PromarkerEso tests. Approximately $1 million is allocated for the Australian launch, $1.5 million for the US launch, another $1 million for system upgrades, and $1.5 million for US laboratory establishment. The remaining $500,000 will support working capital and offer costs.
This capital injection is critical as Proteomics International seeks to expand its footprint in the competitive medical diagnostics sector, leveraging its proprietary Promarker technology. The inclusion of free attaching options provides additional upside potential for investors if the company’s growth initiatives succeed.
Governance and Participation
The company is also seeking shareholder approval for directors and key management personnel to participate in the placement on the same terms as other investors, potentially raising an additional $500,000. This move signals confidence from the leadership in the company’s prospects.
Shareholders are advised to consider the speculative nature of the investment and seek independent financial advice. The company cautions that share prices may fluctuate between the offer announcement and the issue date, affecting the value of shares acquired under the plan.
Bottom Line?
Proteomics International’s capital raise sets the stage for ambitious growth, but shareholder uptake and market response will be key to watch.
Questions in the middle?
- Will shareholder approval for director participation be secured, and how will it impact the raise?
- How will the company manage potential oversubscriptions and scale-backs in the Share Purchase Plan?
- What are the market’s expectations for the commercial success of the Promarker test launches?